Status:
COMPLETED
Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812
Lead Sponsor:
GlaxoSmithKline
Conditions:
Schizophrenia
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purposes of this study are to determine if there is a difference in how SB-773812 is distributed through the bloodstream before and after multiple doses of ketoconazole have been given and to dete...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy
- Body Weight \>/=50kg and BMI 18.5-29.9 kg/m2 inclusive
- Normal 12-lead ECG, physical examination and lab screen
- Exclusion criteria:
- A history of psychiatric illness,
- A history or presence gastro-intestinal,
- A hepatic or renal disease or orthostatic hypotension.
Exclusion
Key Trial Info
Start Date :
October 13 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 10 2007
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00411866
Start Date
October 13 2006
End Date
October 10 2007
Last Update
August 3 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Dundee, United Kingdom, DD1 9SY